Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | NOS2 | P35228 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 3/20 | 0.48 |
| ▸ | CDK4 | P11802 | 3/20 | 0.48 |
| ▸ | CCND1 | P24385 | 3/20 | 0.48 |
| ▸ | CDK2 | P24941 | 3/20 | 0.48 |
| ▸ | NOS1 | P29475 | 3/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23185880 | 0.89 | ALDH1A1 (0.56) | MAPTALDH1A1NPC1MAPK1HTT | |
| SCHEMBL3782855 | 0.86 | ALDH1A1 (0.53) | MAPTNOS2ALDH1A1NPC1MAPK1 | |
| SCHEMBL3776289 | 0.85 | ALDH1A1 (0.54) | MAPTALDH1A1NPC1MAPK1HTT | |
| SCHEMBL12939727 | 0.85 | GRIN2B (0.52) | MAPTNPSR1ALDH1A1ATMLMNA | |
| SCHEMBL30914985 | 0.85 | ALDH1A1 (0.56) | MAPTALDH1A1NPC1MAPK1HTT | |
| SCHEMBL30423002 | 0.84 | CDK2 (0.52) | MAPTNPSR1NOS2ALDH1A1CDK1 | |
| SCHEMBL25213520 | 0.84 | CDK2 (0.52) | MAPTNPSR1NOS2ALDH1A1CDK1 | |
| SCHEMBL23094550 | 0.83 | GPR119 (0.54) | MAPTNPSR1ALDH1A1ATMLMNA | |
| SCHEMBL4730700 | 0.83 | HDAC1 (0.57) | MAPTALDH1A1NPC1MAPK1HTT | |
| SCHEMBL24992878 | 0.83 | ATM (0.46) | MAPTNPSR1ATMGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3725787-B1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230348389-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348389-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11702389-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702389-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210179559-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2021-06-17 | — | — | US | disclosed |
| US-10968180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3292113-B1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10358421-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2019-07-23 | — | — | US | disclosed |
| US-10239837-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180022702-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | ACETYLON PHARMACEUTICALS, INC. | 2018-01-25 | — | — | US | disclosed |
| US-20180022702-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | ACETYLON PHARMACEUTICALS, INC. | 2018-01-25 | — | — | US | disclosed |
| US-20170369441-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2017-12-28 | — | — | US | disclosed |
| US-9790180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160168093-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160168093-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160137630-A1 | INDUCTION OF GATA2 BY HDAC1 AND HDAC2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137630-A1 | INDUCTION OF GATA2 BY HDAC1 AND HDAC2 INHIBITORS | GATAD2B, GATAD2A, HDAC2 | MAPT 636/4885NPSR1 3439/4885NOS2 539/4885 |
| US-20160168093-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | MAPT 1675/4885NPSR1 3883/4885NOS2 1395/4885 |
| US-20170369441-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | MAPT 1675/4885NPSR1 3883/4885NOS2 1395/4885 |
| US-20210179559-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | MAPT 1675/4885NPSR1 3883/4885NOS2 1395/4885 |
| US-11702389-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | MAPT 1675/4885NPSR1 3883/4885NOS2 1395/4885 |
| US-20230348389-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | MAPT 1675/4885NPSR1 3883/4885NOS2 1395/4885 |
| US-10968180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | MAPT 1675/4885NPSR1 3883/4885NOS2 1395/4885 |
| US-10239837-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | MAPT 1675/4885NPSR1 3883/4885NOS2 1395/4885 |
| US-10358421-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | MAPT 1675/4885NPSR1 3883/4885NOS2 1395/4885 |
| US-20180022702-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | MAPT 1675/4885NPSR1 3883/4885NOS2 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.